Trials / Completed
CompletedNCT05596747
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Chinese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Chinese participants with type 2 diabetes mellitus who are on a stable dose of basal insulin. Side effects and tolerability will be documented. Blood samples will be taken to assess how the body processes the study drug and the effect of the study drug on blood sugar levels. The study will last up to 18 weeks and may include 18 visits for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 | Administered SC. |
| DRUG | Insulin Glargine | Administered SC. |
Timeline
- Start date
- 2022-11-30
- Primary completion
- 2023-10-10
- Completion
- 2023-10-10
- First posted
- 2022-10-27
- Last updated
- 2024-01-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05596747. Inclusion in this directory is not an endorsement.